Johnson & Johnson (JNJ) announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension in a broad population of antibody-positive adults with generalized myasthenia gravis reinforcing the efficacy, sustained disease control and safety profile of IMAAVY. Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+. Patients achieving sustained minimal symptom expression experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 study.
"As demonstrated in our pivotal trial, IMAAVY was shown to deliver sustained disease control in a broad population of people living with gMG, helping to address a critical unmet need," said Chris Gasink, Vice President, Medical Affairs, Autoantibody & Gastroenterology, Johnson & Johnson.
Johnson & Johnson previously announced plans to initiate EPIC in 2025. The study, comparing the efficacy of IMAAVY versus efgartigimod, is now enrolling participants.
In pre-market trading on NYSE, Johnson & Johnson shares are down 0.50 percent to $225.00.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.